These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10404797)

  • 1. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes.
    Attia N; Caprio S; Jones TW; Heptulla R; Holcombe J; Silver D; Sherwin RS; Tamborlane WV
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2324-8. PubMed ID: 10404797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes.
    Hedman CA; Orre-Pettersson AC; Lindström T; Arnqvist HJ
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):107-12. PubMed ID: 11453959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion.
    Shishko PI; Dreval AV; Abugova IA; Zajarny IU; Goncharov VC
    Diabetes Res Clin Pract; 1994 Aug; 25(1):1-12. PubMed ID: 7530621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM.
    Hanaire-Broutin H; Sallerin-Caute B; Poncet MF; Tauber M; Bastide R; Chalé JJ; Rosenfeld R; Tauber JP
    Diabetologia; 1996 Dec; 39(12):1498-504. PubMed ID: 8960832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of an intravenous infusion of IGF-I and insulin on IGFBP-1, IGFBP-3, acid labile subunit, free and bound IGF-I, catecholamines and potassium in normal volunteers during an amino acid and glucose clamp.
    Russell-Jones DL; Umpleby AM; Shojaee-Moradie F; Boroujerdi MA; Jones RH; Baxter RC; Sönksen PH
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):685-91. PubMed ID: 9497875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens.
    Yagasaki H; Kobayashi K; Saitou T; Nagamine K; Mitsui Y; Mochizuki M; Kobayashi K; Cho H; Ohyama K; Amemiya S; Nakazawa S
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):195-9. PubMed ID: 19834874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2493-501. PubMed ID: 27115061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity.
    Attia N; Tamborlane WV; Heptulla R; Maggs D; Grozman A; Sherwin RS; Caprio S
    J Clin Endocrinol Metab; 1998 May; 83(5):1467-71. PubMed ID: 9589640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment.
    Spagnoli A; Chiarelli F; Vorwerk P; Boscherini B; Rosenfeld RG
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):587-96. PubMed ID: 10594519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum leptin and the insulin-like growth factor-I system in humans.
    Grégoire Nyomba BL; Johnson M; Berard L; Murphy LJ
    Metabolism; 1999 Jul; 48(7):840-4. PubMed ID: 10421222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children.
    Bereket A; Lang CH; Blethen SL; Ng LC; Wilson TA
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):321-6. PubMed ID: 8949570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor binding proteins in prepubertal children with insulin-dependent diabetes mellitus.
    Knip M; Tapanainen P; Pekonen F; Blum WF
    Eur J Endocrinol; 1995 Oct; 133(4):440-4. PubMed ID: 7581967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery.
    Cotterill AM; Mendel P; Holly JM; Timmins AG; Camacho-Hübner C; Hughes SC; Ross RM; Blum WF; Langford RM
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):91-101. PubMed ID: 8706300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans.
    Porcellati F; Rossetti P; Candeloro P; Lucidi P; Cioli P; Andreoli AM; Ghigo E; Bolli GB; Fanelli CG
    J Clin Endocrinol Metab; 2009 Aug; 94(8):3017-24. PubMed ID: 19470629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus.
    Cheetham TD; Holly JM; Baxter RC; Meadows K; Jones J; Taylor AM; Dunger DB
    J Endocrinol; 1998 Apr; 157(1):81-7. PubMed ID: 9614361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes.
    Frystyk J; Skjaerbaek C; Vestbo E; Fisker S; Orskov H
    Diabetes Metab Res Rev; 1999; 15(5):314-22. PubMed ID: 10585616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.